Goggles Target Pressure Differentials in Glaucoma

The idea for Equinox, and the first non-surgical, non-drug treatment for glaucoma, came to John Berdahl, MD, while he and his wife were scuba diving. People with high intraocular pressure (IOP) could wear the company’s Balance Goggles overnight to alleviate pressure on and around the optic nerve. Dr. Berdahl, Equinox founder and CEO, reported on…

Read More

What the Heck Happened at OIS@ASCRS? – OIS Podcasts Hit Some Highlights from Last Week’s Stellar Meeting in New Orleans

What the Heck Happened at OIS@ASCRS? OIS Podcasts Hit Some Highlights from Last Week’s Stellar Meeting in New Orleans - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 085″] The fifth OIS@ASCRS delivered highlights on diagnostics, glaucoma devices, and What The Future of ophthalmology might bring. OIS Podcasts will provide a quick review of the day for those who couldn’t make it (or simply had overstuffed their meeting calendar in New Orleans). Tom Salemi: Hi, Everyone, welcome back to…

Read More

The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs

The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs - OIS@ASCRS 2016

OIS co-chairs and VCs Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, sit down with OISTV to review the highlights of the May 5 OIS@ASCRS in New Orleans. Topics include the purpose for OIS, plans for future meetings, and advances in ophthalmology treatments. Video Timestamp: 00:52 – The benefit of the breakout sessions.…

Read More

Avedro Finally Secures FDA Approval

Avedro Finally Secures FDA Approval - Eye on Innovation Article

On Monday, Avedro Inc. announced the US Food and Drug Administration finally gave a green light for its KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus. This is a story we’ve been following at OIS.net. According to the company, keratoconus is a progressive thinning and distortion of the cornea. It is…

Read More

Frinzi Shares a Bit of His Plans for AMO

OIS - Podcast - Eye on Innovation

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 079″] Following his successful exit from WaveTec, Tom Frinzi joined Abbott as a senior vice president and head of AMO. In this exclusive interview with OIS, Frinzi shares his motivations and what he’d like to see AMO become. 10 Top Topics in this OIS Podcast: Ophthalmology is in his DNA. Spent…

Read More

Close-Up Look at Progress in Surgical Presbyopia Correction

Close-Up Look at Progress in Surgical Presbyopia Correction - OIS News

Presbyopia, the age-related loss of accommodation and near/reading vision, typically begins at about age 40 and affects nearly everyone over age 50. This huge opportunity is inviting several companies to pursue disruptive approaches. Stephen Lane, MD, from the University of Minnesota, opened the Breakfast Breakout session at OIS@AAO with an overview of current presbyopia treatment…

Read More

Glaucoma Getting a Wake-Up Call

Glaucoma Getting a Wake-Up Call

SAN FRANCISCO — Thanks to a pending boom in minimally invasive glaucoma surgery (MIGS) devices, the global glaucoma device market is poised to come out of its long slumber and triple over the next five years, participants at the fifth annual “Glaucoma 360-New Horizons Forum” heard. Sponsored by the non-profit Glaucoma Research Foundation, the forum…

Read More

Taking in the View of 2015 & Beyond

Taking in the View of 2015 & Beyond

This year’s Ophthalmology Innovation Summits are behind us. We’re piling content onto OIS.NET including the 2015 Year in Review by OIS Founder and Co-Chair Emmett Cunningham, MD. And, believe it or not, we’re eagerly accepting registration for our next OIS@ASCRS, which will be held on May 5 at the InterContinental New Orleans. (We are now…

Read More

Exploring Novartis’ Interest in Medtech

Reza Zadno, PhD, EIR at InterWest Partners explains his new role at the Novartis Venture Fund. He’ll advise the pharma company on where to commit its considerable dollars in Medtech. Novartis, which own Alcon, historically has invested in Medtech and has done a nice job investing in companies like Zadno’s Visiogen. Speaking With: Reza Zadno…

Read More

A View of the Public Ophthalmology Market & Exit Trends

Presenter: Joseph Gilliam Mr. Gilliam has over 16 year’s experience in strategic advisory services, private and public equity and debt financings. Prior to J.P. Morgan, Mr. Gilliam was at The Beacon Group, a strategic advisory and private equity firm. View Full Profile

Read More

Amblyotech

Amblyotech CEO Joseph Koziak describes the company as a “hybrid” life science and software company that is refining its tablet-based treatment platform for amblyopia in adolescents and adults. Its Dig Rush is the first therapeutic video game that treats amblyopia, Koziak said at OIS@AAO 2015. It’s an alternative to patching, which can cost up to…

Read More

ALPHAEON

In the world of self-pay physician services, connecting patients and providers on a broad scale has been difficult, but with the introduction of its ShoutMD platform and the launch of a direct-to-consumer ad campaign, Alphaeon Corp. is creating what CEO Robert E. Grant called “a whole ecosystem” that aims to do that and more for…

Read More